Issued on behalf of Aleen Inc.
VANCOUVER – Baystreet.ca News Commentary – Artificial intelligence is turning fragmented health data into actionable insights, fundamentally reshaping how patients, providers, and platforms understand well-being across the entire healthcare spectrum[1]. Federal agencies are positioning AI as a central driver in improving health outcomes, with the technology now embedded in clinical diagnostics, chronic disease management, drug development, and personal wellness monitoring[2]. This convergence is creating investment opportunities across publicly traded companies deploying AI-powered solutions, including Medtronic plc (NYSE: MDT), Abbott Laboratories (NYSE: ABT), RadNet, Inc. (Nasdaq: RDNT), and WELL Health Technologies Corp. (TSX: WELL) (OTCQX: WHTCF). In parallel, non-medical wellness platforms such as Aleen Inc. (CSE: ALEN-U) operate in a separate category, focusing solely on general well-being insights rather than clinical or diagnostic functions.
The AI healthcare market is projected to surge from $21.66 billion in 2025 to $110.61 billion by 2030 at a 38.6% CAGR[3], driven by the explosion of wearable sensors, electronic health records, and genomic data requiring intelligent interpretation. Regulatory frameworks are accelerating adoption with FDA-cleared AI devices nearly doubling from 400 in 2020 to over 950 by 2024[4], creating favorable conditions for companies that can transform complex datasets into personalized, predictive intelligence across clinical and consumer applications.
Aleen Inc. (CSE: ALEN-U), a Canadian digital wellness company, recently emphasized its commitment to personal reflection and self-awareness rather than medical assessment. The company clarified that its Wellness AI platform focuses on helping users notice habits, reflect on daily experiences, and uncover individual patterns without providing medical diagnoses or clinical assessments.
"Our goal is to help people observe themselves with clarity," said Oleksandr Luzin, Director of Aleen Inc. "Wellness AI is not about diagnosis — it is about reflection, insight, and discovering what your own patterns can teach you."
The company previously announced the development of a personal account system designed to redefine how individuals interact with their wellness data. The upcoming personal account will serve as an intuitive hub where users can seamlessly upload, manage, and visualize their non-medical well-being information.
"Our current focus is on understanding how an analytical tool can responsibly support everyday well-being — while staying entirely outside the realm of diagnostic or medical functions," said Anastasiia Kalashnik, PR Specialist of Aleen Inc. "We are laying the groundwork for a feature that inspires awareness and self-reflection, not prescribes actions."
Based in Ontario, Aleen Inc. went public in June 2025 and has developed an AI platform designed to help users understand their inputs and wellness indicators. The company operates in a rapidly expanding market, with the global digital wellness sector currently valued at approximately $12.87 billion in 2025 and projected to grow to $45.65 billion by 2034, representing annual growth of 15.1%. With about 57% of consumers now using digital apps and wearable devices to monitor their well-being, Aleen is positioned to capture a portion of this expanding demand.
The Aleen AI system can be accessed in two ways. Users can visit the Aleen website for free wellness insights, which helps raise awareness and encourages active engagement with personal well-being. Businesses can integrate Aleen's technology via its API, allowing wellness apps and digital platforms to embed the AI-powered insights into their own services. The company generates revenue through its API offerings, available through a per-call option for businesses paying only for requests used, and a monthly subscription for consistent access.
Looking ahead to 2026, Aleen plans to launch the personal user accounts currently in development alongside the smart analytics features being tested. To fund these initiatives, Aleen is currently seeking between $20 million and $30 million in strategic investment, with plans to allocate 35% toward technology development, 30% toward sales and marketing efforts, and 20% for product expansion.
With 12,643,300 common shares currently issued and outstanding, Aleen Inc. continues to build its presence in the digital wellness space under the leadership of CEO Inna Aksman. The company emphasizes that its platform is designed for preliminary wellness insights only and is not intended to replace consultations with healthcare professionals.
CONTINUED… Read this and more news for Aleen Inc. at: https://usanewsgroup.com/2025/10/25/ai-engine-replaces-the-waiting-room-powering-the-660b-health-revolution/
Medtronic plc (NYSE: MDT) has begun broad U.S. commercial launch of its MiniMed™ 780G system integrated with the Instinct sensor made by Abbott Laboratories (NYSE: ABT), now shipping to customers nationwide following FDA clearance earlier this year. The Instinct sensor, based on Abbott's most advanced continuous glucose monitoring technology, features the world's smallest and thinnest design with up to 15 days of wear time and pairs with the MiniMed™ 780G system to automate insulin adjustments every five minutes based on real-time glucose readings.
"Bringing together the Instinct sensor, made by Abbott, with the excellent algorithm of the MiniMed™ 780G system creates an extremely effective combination," said Dr. Steve Edelman, founder and director of Taking Control of Your Diabetes. "With the MiniMed™ 780G system, my patients have seen improved time in range and now with the Instinct sensor it's a seamless experience."
The launch expands Medtronic's sensor portfolio alongside the recently launched Simplera Sync™ sensor and the Guardian™ 4 sensor, building a growing ecosystem designed to make diabetes care easier and more personalized. The integration delivers a smart dosing system that helps people with diabetes spend less time managing their condition through automated insulin delivery that adjusts based on real-time data, reducing highs and lows while improving overall glucose control.
"This milestone marks an important next step in our work to bring the proven clinical outcomes of our MiniMed™ 780G system to more people living with diabetes," said Que Dallara, EVP and president of Medtronic Diabetes. "With this launch, we're expanding a smart dosing ecosystem built for choice, so every person can find a solution that fits their life."
DeepHealth, a wholly owned subsidiary of RadNet, Inc. (Nasdaq: RDNT), launched the Breast Suite, a comprehensive, modular AI-powered suite of applications supporting more than 10 million mammograms annually with increased breast cancer detection rates, risk stratification tools, and accelerated workflow capabilities. The largest real-world analysis of AI-powered breast cancer screening in the US, published in Nature Health and covering mammograms from over 579,000 women across 100+ community-based imaging sites, demonstrated that DeepHealth Breast Suite applications enabled a 21% increase in breast cancer detection rate, including 23% more cancers detected in women with dense breasts and 20% more cancers detected in Black, non-Hispanic women.
"The launch of Breast Suite marks a pivotal step toward a new, AI-powered standard of care in breast cancer screening and diagnostic pathways," said Kees Wesdorp, CEO of RadNet's Digital Health Division, DeepHealth. "By embedding detection and risk intelligence with workflow tools, we give radiologists more capabilities to detect cancers earlier, with more confidence and to elevate patient care."
Breast Suite integrates leading AI-powered cancer detection with automated density assessment, AI-powered risk assessment that identifies risk of developing breast cancer in 1-2 years with 2x greater accuracy than traditional questionnaire-based risk models, and breast arterial calcification assessment currently in development. The platform includes cloud-first multi-modality viewing, prioritized worklists, timely alerts that flag high suspicion cases within minutes, and AI-powered Safeguard Review workflow that decreases false negatives.
WELL Health Technologies Corp. (TSX: WELL) (OTCQX: WHTCF) reported strong organic growth across its Canadian Patient Services business, achieving quarterly revenue of over $110 million with 41% year-over-year growth and same-clinic revenue increases of 10% for medical centres and 16% for diagnostic centres. The company disclosed it has achieved 92% digitization across all primary care clinics in its network for longer than nine months, while successfully filling 25,000 of the 45,000 new primary care patient openings announced in June 2025.
"We take clinic transformation very seriously and have a highly methodical way of approaching our digitization plans," said Jeremy Mickolwin, Vice President of Clinic Operations at WELL. "Our goal is to ensure that every clinic in our network has achieved its 'core digitization' within a year of operations. Our definition of 'core' will likely expand as our new AI enabled applications are being rapidly deployed and driving significant new benefits for providers."
The company expects to fully satisfy the remaining patient openings by the end of Q1 2026, which would create accessibility for 270,000 new yearly patient visits. WELL's digitization initiatives include online patient booking, self-check-in, automated patient reminders, and digital consent management, with the majority of tools developed by WELLSTAR Technologies Corp.
Article Sources: https://usanewsgroup.com/2025/10/25/ai-engine-replaces-the-waiting-room-powering-the-660b-health-revolution/
CONTACT:
Baystreet.ca
[email protected]
(805) 649-0042
DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. (“MIQ”). MIQ has been paid a fee for Aleen Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares Aleen Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Aleen Inc. which were purchased in the open market. MIQ reserves the right to buy and sell, and will buy and sell shares of Aleen Inc. at any time thereafter without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by MIQ has been approved by the above mentioned company; this is a paid advertisement, and we own shares of the mentioned company that we will sell, and we also reserve the right to buy shares of the company in the open market, or through other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment. Aleen’s solutions operate within the wellness domain and are not subject to FDA or Health Canada approval. The platform provides wellness insights based on user inputs and is not intended to diagnose, treat, or prevent any medical condition.
--
SOURCES CITED:
1. https://www.mindbodygreen.com/articles/how-ai-is-turning-your-health-data-into-actionable-insights
2. https://www.hklaw.com/en/insights/publications/2025/12/hhs-releases-strategy-positioning-artificial-intelligence
3. https://www.marketsandmarkets.com/Market-Reports/artificial-intelligence-healthcare-market-54679303.html
https://intuitionlabs.ai/articles/ai-medical-devices-regulation-2025